Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism.
作者信息
Abou-Ismail Mouhamed Yazan, Moser Karen A, Smock Kristi J, Lim Ming Y
机构信息
Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
出版信息
Am J Hematol. 2021 Sep 1;96(9):E346-E349. doi: 10.1002/ajh.26265. Epub 2021 Jun 17.
Abstract
摘要
相似文献
1
Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism.一名表现为急性静脉血栓栓塞的男性在接种Ad26.COV2.S疫苗后出现疫苗诱导的血栓性血小板减少症。
Am J Hematol. 2021 Sep 1;96(9):E346-E349. doi: 10.1002/ajh.26265. Epub 2021 Jun 17.
2
Vaccine-Induced Immune Thrombotic Thrombocytopenia with Concurrent Arterial and Venous Thrombi Following Ad26.COV2.S Vaccination.接种Ad26.COV2.S疫苗后并发动脉和静脉血栓形成的疫苗诱导免疫性血栓性血小板减少症
J Stroke Cerebrovasc Dis. 2021 Dec;30(12):106113. doi: 10.1016/j.jstrokecerebrovasdis.2021.106113. Epub 2021 Sep 20.
3
Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination.接种 Ad26.COV2.S 疫苗后，比伐卢定治疗血栓性血小板减少性紫癜和脑静脉窦血栓形成的早期结果。
Ann Emerg Med. 2021 Oct;78(4):511-514. doi: 10.1016/j.annemergmed.2021.04.035. Epub 2021 Jul 3.
4
Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.接种 BNT162b2、ChAdOx1 nCoV-19 和 Ad26.COV2.S 疫苗后的心血管、神经和肺部事件：欧洲数据分析。
J Autoimmun. 2021 Dec;125:102742. doi: 10.1016/j.jaut.2021.102742. Epub 2021 Oct 26.
5
Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis.新型冠状病毒病疫苗诱导的免疫性血栓性血小板减少症的血栓形成模式和临床结局：系统评价和荟萃分析。
Int J Infect Dis. 2022 Jun;119:130-139. doi: 10.1016/j.ijid.2022.03.034. Epub 2022 Mar 24.
6
Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy.Ad26.COV2.S疫苗接种后出现血小板减少症和内脏血栓形成，经颈静脉肝内门体分流术和血栓切除术成功治疗。
Am J Hematol. 2021 Sep 1;96(9):1180-1182. doi: 10.1002/ajh.26258. Epub 2021 Jun 14.
7
Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.2020 年 12 月至 2021 年 8 月美国 COVID-19 疫苗接种后血栓性血小板减少综合征病例系列报告。
Ann Intern Med. 2022 Apr;175(4):513-522. doi: 10.7326/M21-4502. Epub 2022 Jan 18.
8
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.Ad26.COV2.S疫苗接种后血栓性血小板减少症
N Engl J Med. 2021 May 20;384(20):1964-1965. doi: 10.1056/NEJMc2105869. Epub 2021 Apr 14.
9
Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US.接种 Ad26.COV2.S 后发生致命性疫苗诱导的免疫性血栓性血小板减少症（VITT）：首例美国以外的确诊病例。
Infection. 2022 Apr;50(2):531-536. doi: 10.1007/s15010-021-01712-8. Epub 2021 Oct 9.
10
Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.不同 COVID-19 疫苗相关的血栓性血小板减少综合征或血栓栓塞事件的比较风险：来自五个欧洲国家和美国的国际网络队列研究。
BMJ. 2022 Oct 26;379:e071594. doi: 10.1136/bmj-2022-071594.
引用本文的文献
1
The Impact of COVID-19 and the Practical Importance of Vaccinations and Nirmatrelvir/Ritonavir for Patients with Cardiovascular Disease.新冠病毒病（COVID-19）的影响以及疫苗接种和奈玛特韦/利托那韦对心血管疾病患者的实际重要性
Vaccines (Basel). 2025 May 23;13(6):554. doi: 10.3390/vaccines13060554.
2
A systemic review and recommendation for an autopsy approach to death followed the COVID 19 vaccination.一项针对 COVID-19 疫苗接种后死亡的尸检方法的系统回顾和建议。
Forensic Sci Int. 2022 Nov;340:111469. doi: 10.1016/j.forsciint.2022.111469. Epub 2022 Sep 20.
3
Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.接种 COVID-19 疫苗后的自身免疫和自身炎症性疾病。新病例报告和最新文献回顾。
J Autoimmun. 2022 Oct;132:102898. doi: 10.1016/j.jaut.2022.102898. Epub 2022 Aug 24.
4
Comparison of replicating and nonreplicating vaccines against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的复制型疫苗与非复制型疫苗的比较。
Sci Adv. 2022 Aug 26;8(34):eabm8563. doi: 10.1126/sciadv.abm8563. Epub 2022 Aug 24.
5
Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT.单克隆和寡克隆抗血小板因子 4 抗体介导 VITT。
Blood. 2022 Jul 7;140(1):73-77. doi: 10.1182/blood.2021014588.
6
Longitudinal Aspects of VITT.VITT 的纵向方面。
Semin Hematol. 2022 Apr;59(2):108-114. doi: 10.1053/j.seminhematol.2022.03.001. Epub 2022 Mar 7.
7
Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT.BNT162b2 mRNA疫苗加强针在与Ad26.COV2.S相关的疫苗诱导的免疫性血小板减少症背景下的安全性
Blood Adv. 2022 Sep 27;6(18):5327-5329. doi: 10.1182/bloodadvances.2022007753.
8
Cerebral Venous Sinus Thrombosis due to Thrombosis with Thrombocytopenia Syndrome Following Ad26.COV2.S: A First Real-World Case Report of a Male Subject.Ad26.COV2.S接种后血栓形成伴血小板减少综合征所致的脑静脉窦血栓形成：一例男性受试者的首例真实病例报告
Neurohospitalist. 2022 Apr;12(2):346-351. doi: 10.1177/19418744211055065. Epub 2021 Dec 23.
9
Refined Capsid Structure of Human Adenovirus D26 at 3.4 Å Resolution.人腺病毒 D26 的精细衣壳结构在 3.4 Å 分辨率下。
Viruses. 2022 Feb 17;14(2):414. doi: 10.3390/v14020414.
10
Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies.Ad26.COV2.S 相关疫苗诱导的免疫性血栓性血小板减少症（VITT）的持续存在和 VITT 抗体的特异性检测。
Am J Hematol. 2022 May;97(5):519-526. doi: 10.1002/ajh.26488. Epub 2022 Feb 21.
本文引用的文献
1
Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT).疫苗诱导的免疫性血小板减少症和血栓形成（VITT）
Res Pract Thromb Haemost. 2021 Jun 1;5(5):e12529. doi: 10.1002/rth2.12529. eCollection 2021 Jun.
2
Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination.评价 ChAdOx1 nCOV-19 疫苗接种后抗血小板因子 4 抗体的实验室检测。
J Thromb Haemost. 2021 Aug;19(8):2007-2013. doi: 10.1111/jth.15362. Epub 2021 Jul 5.
3
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.美国 2021 年 3 月 2 日至 4 月 21 日 Ad26.COV2.S 疫苗接种后出现脑静脉窦血栓形成伴血小板减少的病例报告。
JAMA. 2021 Jun 22;325(24):2448-2456. doi: 10.1001/jama.2021.7517.
4
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021.美国 2021 年 4 月：在报告接种强生（Johnson & Johnson）新冠疫苗的人群中出现血栓性血小板减少综合征后，免疫实践咨询委员会更新了强生疫苗的使用建议。
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656. doi: 10.15585/mmwr.mm7017e4.
5
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.接种 ChAdOx1 nCoV-19 疫苗后对血小板因子 4 的病理性抗体。
N Engl J Med. 2021 Jun 10;384(23):2202-2211. doi: 10.1056/NEJMoa2105385. Epub 2021 Apr 16.
6
SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.严重急性呼吸综合征冠状病毒2型疫苗诱导的免疫性血栓性血小板减少症
N Engl J Med. 2021 Jun 10;384(23):2254-2256. doi: 10.1056/NEJMe2106315. Epub 2021 Apr 16.
7
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer.Ad26.COV2.S疫苗接种后血栓性血小板减少症——来自制造商的回应
N Engl J Med. 2021 May 20;384(20):1965-1966. doi: 10.1056/NEJMc2106075. Epub 2021 Apr 16.
8
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
9
Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.接种阿斯利康 COVID-19 疫苗后的疫苗相关血栓形成的诊断和管理：GTH 的指导意见声明。
Hamostaseologie. 2021 Jun;41(3):184-189. doi: 10.1055/a-1469-7481. Epub 2021 Apr 1.
Zotero 插件